


Claims:

1. A compound according to Formula I:



5

and pharmaceutically and/or veterinarily acceptable derivatives thereof,  
wherein:

R<sup>1</sup> is H;

- 10 R<sup>2</sup> is aryl, het, C<sub>3-8</sub>cycloalkyl, C<sub>1-6</sub>alkyl, (CH<sub>2</sub>)<sub>z</sub>aryl or R<sup>4</sup>, wherein each of the cycloalkyl, aryl, het and R<sup>4</sup> groups is optionally substituted by at least one substituent independently selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, OH, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, O(CH<sub>2</sub>)<sub>y</sub>CF<sub>3</sub>, CN, CONH<sub>2</sub>, CON(H)C<sub>1-6</sub>alkyl, CON(C<sub>1-6</sub>alkyl)<sub>2</sub>, hydroxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-4</sub>alkoxy, SCF<sub>3</sub>, C<sub>1-6</sub>alkylSO<sub>2</sub>, C<sub>1-4</sub>alkyl-S-C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyl-S-,  
15 C<sub>1-4</sub>alkylNR<sup>10</sup>R<sup>11</sup> and NR<sup>10</sup>R<sup>11</sup>;

or R<sup>1</sup> and R<sup>2</sup>, together with the carbon atom to which they are bound, form a 5- or 6-membered carbocyclic ring or a 5- or 6-membered heterocyclic ring containing at least one N, O or S heteroatom;

- 20 where R<sup>1</sup> and R<sup>2</sup> are different, \* represents a chiral centre;

R<sup>3</sup> is aryl, het or R<sup>4</sup>, each optionally substituted by at least one substituent independently selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, het, OH, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, O(CH<sub>2</sub>)<sub>y</sub>CF<sub>3</sub>, CN, CONH<sub>2</sub>, CON(H)C<sub>1-6</sub>alkyl, CON(C<sub>1-6</sub>alkyl)<sub>2</sub>, hydroxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-4</sub>alkoxy,  
25 SCF<sub>3</sub>, C<sub>1-6</sub>alkylSO<sub>2</sub>, C<sub>1-4</sub>alkyl-S-C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyl-S-, C<sub>1-4</sub>alkylNR<sup>10</sup>R<sup>11</sup> and NR<sup>10</sup>R<sup>11</sup>;

R<sup>4</sup> is a phenyl group fused to a 5- or 6-membered carbocyclic group, or a phenyl group fused to a 5- or 6-membered heterocyclic group containing at least one N, O or S heteroatom;

$R^5$  is H or  $C_{1-6}$ alkyl;

$R^{10}$  and  $R^{11}$  are the same or different and are independently H or  $C_{1-4}$ alkyl;

A is a  $C_{1-3}$ alkylene chain which is optionally substituted by OH,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy;

5 x is an integer from 1 to 3;

y is 1 or 2;

z is an integer from 1 to 3;

aryl is phenyl, naphthyl, anthracyl or phenanthryl; and

het is an aromatic or non-aromatic 4-, 5- or 6-membered heterocycle

10 which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6-membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, provided that when  $R^1$  is H,  $R^2$  is phenyl, A is  $CH_2$  and x is 1,  $R^3$  is not 3-hydroxyphenyl or 3-( $C_{1-4}$ alkoxy)phenyl.

15

2. A compound according to Claim 1, wherein  $R^1$  is H.

3. A compound according to Claim 1 or Claim 2, wherein  $R^2$  is aryl, het or  $C_{3-8}$ cycloalkyl, each optionally substituted by at least one substituent  
20 independently selected from  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, OH, halo,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ ,  $O(CH_2)_yCF_3$ , CN,  $CONH_2$ ,  $CON(H)C_{1-6}$ alkyl,  $CON(C_{1-6}alkyl)_2$ , hydroxy- $C_{1-6}$ alkyl,  $C_{1-4}$ alkoxy- $C_{1-6}$ alkyl,  $C_{1-4}$ alkoxy- $C_{1-4}$ alkoxy,  $SCF_3$ ,  $C_{1-6}alkylSO_2$  and  $C_{1-4}alkyl-S-C_{1-4}alkyl$ .

25 4. A compound according to Claim 3, wherein  $R^2$  is aryl optionally substituted by at least one substituent independently selected from  $C_{1-6}alkyl$ ,  $C_{1-6}alkoxy$ , OH, halo,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ ,  $O(CH_2)_yCF_3$ , CN,  $CONH_2$ ,  $CON(H)C_{1-6}alkyl$ ,  $CON(C_{1-6}alkyl)_2$ , hydroxy- $C_{1-6}alkyl$ ,  $C_{1-4}alkoxy-C_{1-6}alkyl$ ,  $C_{1-4}alkoxy-C_{1-4}alkoxy$ ,  $SCF_3$ ,  $C_{1-6}alkylSO_2$  and  $C_{1-4}alkyl-S-C_{1-4}alkyl$ .

30

5. A compound according to Claim 4, wherein  $R^2$  is phenyl optionally substituted by at least one substituent independently selected from  $C_{1-6}alkyl$ ,  $C_{1-6}alkoxy$ , OH, halo,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ ,  $O(CH_2)_yCF_3$ , CN,  $CONH_2$ ,

64

CON(H)C<sub>1-6</sub>alkyl, CON(C<sub>1-6</sub>alkyl)<sub>2</sub>, hydroxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-4</sub>alkoxy, SCF<sub>3</sub>, C<sub>1-6</sub>alkylSO<sub>2</sub> and C<sub>1-4</sub>alkyl-S-C<sub>1-4</sub>alkyl.

6. A compound according to any preceding claim, wherein R<sup>3</sup> is aryl or  
 5 R<sup>4</sup>, each optionally substituted by at least one substituent independently  
 selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, OH, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>,  
 O(CH<sub>2</sub>)<sub>y</sub>CF<sub>3</sub>, CN, CONH<sub>2</sub>, CON(H)C<sub>1-6</sub>alkyl, CON(C<sub>1-6</sub>alkyl)<sub>2</sub>, hydroxy-C<sub>1-  
 6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-4</sub>alkoxy, SCF<sub>3</sub>, C<sub>1-6</sub>alkylSO<sub>2</sub> and  
 C<sub>1-4</sub>alkyl-S-C<sub>1-4</sub>alkyl.

10

7. A compound according to Claim 6, wherein R<sup>3</sup> is phenyl optionally  
 substituted by at least one substituent independently selected from C<sub>1-  
 6</sub>alkyl, C<sub>1-6</sub>alkoxy, OH, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, O(CH<sub>2</sub>)<sub>y</sub>CF<sub>3</sub>, CN, CONH<sub>2</sub>,  
 CON(H)C<sub>1-6</sub>alkyl, CON(C<sub>1-6</sub>alkyl)<sub>2</sub>, hydroxy-C<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxy-C<sub>1-6</sub>alkyl,  
 15 C<sub>1-4</sub>alkoxy-C<sub>1-4</sub>alkoxy, SCF<sub>3</sub>, C<sub>1-6</sub>alkylSO<sub>2</sub> and C<sub>1-4</sub>alkyl-S-C<sub>1-4</sub>alkyl.

8. A compound according to any preceding claim, wherein R<sup>5</sup> is H or  
 C<sub>1-6</sub>alkyl.

- 20 9. A compound according to any preceding claim, wherein A is a  
 methylene (i.e. -CH<sub>2</sub>-) group optionally substituted by OH.

10. A compound according to any preceding claim, wherein x is 1.

- 25 11. A compound according to Claim 1 which is (+) or (-)-1-[2-(2-  
 Ethoxyphenyl)-1-phenylethyl]piperazine.

12. A pharmaceutical composition comprising a compound as claimed  
 in any one of Claims 1 to 11 and a pharmaceutically acceptable adjuvant,  
 30 diluent or carrier.

13. A compound according to any one of Claims 1-11 for use as a  
 medicament.


14. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of a disorder in which the regulation of monoamine transporter function in mammals is implicated.
- 5 15. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of a disorder in which the regulation of serotonin or noradrenaline in mammals is implicated.
- 10 16. Use according to Claim 15, wherein the regulation of serotonin and noradrenaline is implicated.
- 15 17. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia in mammals.
18. Use of a compound according to Claim 17, for the treatment of urinary incontinence, such as GSI or USI , in mammals.
- 20 19. A method of treatment of a disorder in which the regulation of monoamine transporter function is implicated which comprises administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.
- 25 20. A method of treatment of a disorder in which the regulation of serotonin or noradrenaline is implicated which comprises administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.
- 30 21. A method according to Claim 20, wherein the regulation of serotonin and noradrenaline is implicated.
22. A method of treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia, which comprises

66

administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.

23. A method according to Claim 22, wherein the urinary disorder is  
5 urinary incontinence, such as GSI or USI.

24. A process for preparing a compound according to any one of Claims 1-11 comprising reacting a compound of Formula III




(III)

10

wherein R<sup>2</sup> and x are as defined in any of Claims 1 to 11 and PG is a protecting group;

with a compound of Formula IV



(IV)

15 wherein R<sup>3</sup> and A are as defined in any of Claims 1 to 11, M is a metal selected from Zn and Mg and Hal is a halogen atom selected from chlorine, bromine and iodine;  
and deprotecting the resultant compound.

20